HC Wainwright & Co. Reiterates Buy on Insmed, Announces $220 Price Target

HC Wainwright & Co. analyst Andrew S. Fein has reiterated a Buy rating on Insmed (NASDAQ: INSM) and set a price target of $220 for the company's stock.